Cardio-Oncology

Loading the player...

CEO Nancy Brown on Cardio Oncology

CEO Nancy Brown explains why the AHA is funding a Strategically Focused Research Network on cardio-oncology with $15 million and, working with CancerLinQ LLC, making oncology datasets available on a version of the Precision Medicine Platform. Go here for SFRN updates and see the CancerLinQ news report.

Science NewsView All Science News

Public Comment: 2020 ACC/AHA Performance Measures for Adult with Heart Failure
02/07/2020 | We would like to invite you to participate in the review of the draft version of the 2020 ACC/AHA Clinical Performance and Quality Measur...
The AHA 2030 Impact Goal
01/29/2020 | Since the late 1990s, the AHA has committed to a singular impact goal to advance the AHA?s mission for the decade ahead.
Heart Disease and Stroke Statistics - 2020 Update
01/29/2020 | The age-adjusted death rate attributable to cardiovascular disease (CVD), based on 2017 data, is 219.4 per 100,000.
CIRCULATION Editor's Picks | January 2020
01/28/2020 | CIRCULATON Editor's Picks for January 2020

Scientific Sessions 2020

Scientific Sessions: Nov. 14–16
 

Dallas, Texas
 

Related Councils

Council on Clinical Cardiology (CLCD)

Eldrin Lewis, MD, MPH, FAHA, FACC

The purpose of the Council on Clinical Cardiology (CLCD) is to achieve the objectives of the American Heart Association (AHA) in the field of clinical cardiology, to promote excellence in clinical care and to foster the professional development and education of clinical cardiologists. Through council-sponsored symposia, panels and scientific conferences, members can access new developments in the field and interpret and promote clinical cardiology to professional and lay audiences.

Eldrin Lewis, MD, MPH, FAHA, FACC
Chair, Council on Clinical Cardiology

Scientific Sessions       Circulation       CLCD Council Awards

Council on Genomic and Precision Medicine (GPM)

Thomas J. Wang, MD, FAHA

The mission of the American Heart Association Council on Genomic and Precision Medicine (GPM) is to advance the discovery and translation of biological insights gained from genetics and omics technologies to improve cardiovascular and brain health. Our constituency’s expertise spans across genetics, genomics, epigenetics, transcriptomics, metabolomics, proteomics, microbiome, bioinformatics, computational science, population health, clinical genetics and genomic medicine, with the ultimate goal of more precise risk prediction, treatment and prevention for patients and the population. Integral to the American Heart Association’s goals, the GPM Council provides a premier inter-disciplinary forum promoting and integrating new knowledge from molecules to populations in translational cardiovascular science and precision medicine.

Thomas J. Wang, MD, FAHA
Chair, Council on Genomic and Precision Medicine

Scientific Sessions       Circulation: Genomic and Precision Medicine      GPM Council Awards